Form 4: United Therapeutics Director Raymond Dwek Exercises Options and Sells Shares Under 10b5-1 Plan
SEC Form 4
Raymond Dwek, a director at United Therapeutics, exercised stock options and sold the resulting shares according to a pre-arranged 10b5-1 trading plan.
Summary
- On April 21, 2025, Raymond Dwek, a director of United Therapeutics Corp, exercised stock options to acquire 3,000 shares of common stock at a price of $175.43 per share.
- Following the exercise, Dwek sold 3,000 shares of common stock at a price of $285.57 per share.
- These transactions were executed under a pre-arranged 10b5-1 trading plan established on August 2, 2024.
- After these transactions, Dwek directly owns 1,750 shares of United Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document simply reports transactions; it's neutral in sentiment.
Industry Context
Directors often use 10b5-1 plans to avoid accusations of insider trading, allowing them to sell shares at predetermined times and prices.
Key Dates
| Date | Description |
|---|---|
| 06/26/2016 | Original date the stock options became exercisable |
| 08/02/2024 | Date the 10b5-1 plan was entered into by the reporting person |
| 04/21/2025 | Date of stock option exercise and share sale |
| 04/22/2025 | Date of signature on the Form 4 filing |
| 06/26/2025 | Expiration date of the stock options |
Keywords
Form 4, United Therapeutics, UTHR, Raymond Dwek, Stock Options, 10b5-1 Plan, Director, Share Sale
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.